NCT05465174 2026-03-09
PNOC029
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07441707 2026-03-02
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Ipsen
Phase 1 Not yet recruiting
NCT03429803 2026-02-19
DAY101 In Gliomas and Other Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07206849 2025-10-29
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Nationwide Children's Hospital
Phase 2 Not yet recruiting
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT07121829 2025-08-14
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Terminated
NCT04775485 2025-04-10
FIREFLY-1
Day One Biopharmaceuticals, Inc.
Phase 2 Recruiting
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing